Ana Oaknin

Hebron University — PS

Medicine · Health Sciences

71h-index34.9kcitations710works8.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(338), PARP inhibition in cancer therapy(251), Endometrial and Cervical Cancer Treatments(167), Cancer Genomics and Diagnostics(132), Cancer Immunotherapy and Biomarkers(85)

Publications706 total

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Future Oncology·2025· 1 citedOpen Access
Supplementary Figure S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2025Open Access
Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S7 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S6 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
RACIAL SUBGROUP ANALYSES OF TUMOR RESPONSE AND SAFETY IN PATIENTS WITH MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH ADVANCED/RECURRENT ENDOMETRIAL CANCER RECEIVING DOSTARLIMAB MONOTHERAPY IN THE GARNET TRIAL
International Journal of Gynecological Cancer·2025
REJOICE-OVARIAN02: A PHASE 1B/2 STUDY OF RALUDOTATUG DERUXTECAN WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH RELAPSED OVARIAN CANCER AFTER PLATINUM-BASED CHEMOTHERAPY
International Journal of Gynecological Cancer·2025Open Access
PHASE 3 ROSELLA (GOG-3073, ENGOT-OV72) TRIAL OF RELACORILANT + NAB-PACLITAXEL VS NAB-PACLITAXEL IN PLATINUM-RESISTANT OVARIAN CANCER: PRIMARY RESULTS AND OUTCOMES IN OLDER PATIENTS
International Journal of Gynecological Cancer·2025
REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
International Journal of Gynecological Cancer·2025
TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
International Journal of Gynecological Cancer·2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology·2025
page 1 of 36Next →

Frequent Co-authors

Domenica Lorusso(19), Nicoletta Colombo(18), Isabelle Ray‐Coquard(16), Alexandra Léary(15), Amit M. Oza(15), Susana Banerjee(13), Ignace Vergote(13), Giovanni Scambia(12), Kathleen N. Moore(11), Iain A. McNeish(11), Antonio González-Martı́n(10), Carol Aghajanian(10), Robert L. Coleman(10), David M. O’Malley(9), Anne Floquet(8), Sandro Pignata(8), Bradley J. Monk(8), Michael Friedländer(7), Elizabeth M. Swisher(7), Andrés Poveda(7)